News
-
ADmit Therapeutics is Attending the AAIC 2025 in Toronto
July 27, 2025. We are excited to announce that our company is attending the Alzheimer’s Association International Conference 2025 (AAIC25) in Toronto, Canada, from July 27 to July 31, 2025. The AAIC is the world’s largest and most influential meeting dedicated to advancing dementia science. Organized by the Alzheimer’s Association, this global forum brings together researchers, clinicians, and industry leaders to…
-
ADmit Therapeutics SL, one of the 10 most disruptive companies in Catalonia, according to ACCIÓ
Barcelona, July 16, 2025 — The company has been recognized as one of the startups and companies awarded the ‘Catalonia Exponential Leaders’ distinction by ACCIÓ, which acknowledges pioneers in the field of disruptive innovation for their ability to generate a positive impact on society beyond their business models, as well as their potential for exponential growth and adoption…
-
ADmit Therapeutics Relocates to New State-of-the-Art Facilities Within the Almirall’s Innovation Hub “The Hive”
Barcelona, Spain – July 2, 2025 – ADmit Therapeutics, a biotechnology company focused on developing innovative diagnostic solutions for Alzheimer’s disease, today announced its relocation to new, expanded laboratory and office spaces within Almirall’s Innovation Hub “The Hive” at the existing R&D center in Sant Feliu de Llobregat. This strategic move signifies a key milestone for…
-
ADmit Therapeutics receives accreditation from the College of American Pathologists
Barcelona, Spain – November 14, 2024. The Committee on Accreditation of the College of American Pathologists (CAP) has granted accreditation to ADmit Therapeutics, Barcelona, based on the results of the recent on-site inspection conducted as part of CAP’s Accreditation Programmes. The director of the laboratory, Dr. Marta Blanch was notified of this national recognition and…
-
ADmit Therapeutics extends the scope of its ISO13485
ADmit Therapeutics announces that it has successfully passed the annual external audit, demonstrating that the medical device quality management system and its effectiveness are adequately maintained. We are pleased to share that, in our tireless effort to pursue excellence in quality, the scope of our ISO13485:2016 certification has been expanded to include the manufacturing of…
-
ADmit Therapeutics has been selected to join StartUp Health’s Alzheimer’s Moonshot Community.
21 of May, 2024 ADmit Therapeutics, has been selected to be part of the prestigious Alzheimer’s Moonshot Community driven by StartUp Health. This initiative brings together startups, investors and organisations focused on accelerating transformative solutions for the prevention, detection and treatment of Alzheimer’s disease. Through this inclusion, ADmit Therapeutics will have access to a global…
